An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

ID#: NCT04113616

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 1/Phase 2

Recruitment Status: Recruiting

Start Date: September 25, 2019

End Date: July 15, 2024

Contact Information:
Yulia Khalina
908-656-2799
John Mei
650-542-0136
Summary: This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive KRT+232 with LDAC or KRT-232 with Decitabine.
Eligibility: Key

Inclusion Criteria:

- Part A: Patients with relapsed or refractory AML, or newly-diagnosed AML secondary to MPN

- Part B: Patients with AML secondary to MPN or JAK2 mutation positive AML; patients may have been treated with 0 to 2 prior lines of therapy for their AML

- Adequate hepatic and renal function

- Appropriate prior treatment with an FLT3 or IDH1/2 inhibitor where applicable Key

Exclusion Criteria:

- Patients who are TP53 mutation positive

- Prior treatment with an MDM2 antagonist therapy

- Patients treated with ≥ 18 g/m2 of cytarabine within the prior 90 days are not eligible to be treated with cytarabine on this study (but may be treated with decitabine)

- Patients previously treated with decitabine are not eligible to receive decitabine on this study (but may be treated with cytarabine)

- Patients who have received an allogeneic HSCT within 90 days of enrollment or are eligible for an allogeneic HSCT and have a donor (unless transplant is refused)

- Active graft-versus-host disease requiring active therapy or who have received immunosuppressive therapy for graft-versus-host disease within 1 month prior

- Patients with known CNS involvement with AML, acute promyelocytic leukemia (APL), or a history of bleeding diathesis

- Patients who have had major surgery within 28 days prior

- Women who are pregnant or breastfeeding